Ascent Group LLC Acquires 1,056 Shares of Medpace Holdings, Inc. $MEDP

Ascent Group LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,387 shares of the company’s stock after acquiring an additional 1,056 shares during the period. Ascent Group LLC’s holdings in Medpace were worth $10,327,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MEDP. Quent Capital LLC bought a new position in Medpace in the 3rd quarter worth $25,000. Optiver Holding B.V. bought a new stake in Medpace during the third quarter valued at about $27,000. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Quarry LP purchased a new stake in Medpace in the third quarter worth about $35,000. Finally, Root Financial Partners LLC purchased a new stake in Medpace in the third quarter worth about $38,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $498.34 on Friday. The stock has a market cap of $14.14 billion, a price-to-earnings ratio of 32.57, a price-to-earnings-growth ratio of 2.39 and a beta of 1.39. The stock has a 50 day moving average price of $482.05 and a 200-day moving average price of $537.23. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on MEDP. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Leerink Partners dropped their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.